A new microwave-assisted, three-component reaction of 5-aminopyrazole-4-carboxylates:selective synthesis of substituted 5-aza-9-deaza-adenines by Lim, Felicia Phei Lin et al.
A new microwave-assisted, three-component reaction of 5-aminopyrazole-4-carboxylates: 
selective synthesis of substituted 5-aza-9-deaza-adenines1  
 
Felicia Phei Lin Lima, Nathan R. Halcovitchb, Edward R. T. Tiekinkc, and Anton V. Dolzhenkoa,d 
a School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor 
DarulEhsan 47500, Malaysia  
b Department of Chemistry, Lancaster University, Lancaster LA1 4YB, United Kingdom 
c Research Centre for Crystalline Materials, School of Science and Technology, Sunway University, 
Bandar Sunway, Selangor Darul Ehsan 47500, Malaysia 
d School of Pharmacy, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin 
University, GPO Box U1987 Perth, Western Australia 6845, Australia 
  
Graphical Abstract 
 
HC(OEt)3
+ NH2N
150 °C, 25 minMeOH
N NH
NH NH2
O OR2+
N
N
NN
NH2
HN
O OR2
R1 R1
Yields up to 95%
24 examples
0.24 to 2.3 g scale
 
 
Abstract 
A series of 5-aza-9-deaza- analogues of purine was effectively prepared using highly selective 
annulation of 1,3,5-triazine ring onto 5-aminopyrazole-4-carboxylates via a one-pot, 
multicomponent, microwave-assisted approach. The products were obtained in good yields and high 
purity. This catalyst-free method was demonstrated to be scalable and highly reproducible in 
different microwave reactors. Some structural features of the prepared compounds were studied in 
details using dynamic NMR spectroscopy and X-ray crystallography.  
 
Highlights 
- A practical synthesis of adenine analogues 
- A new scalable and reproducible microwave-assisted synthesis 
- Hindered rotation study by dynamic NMR spectroscopy   
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1. Introduction 
Isosterism and bioisosterism have been proven to be efficient strategies in the drug discovery 
process. The isosteric replacement of biologically important heterocyclic scaffolds with structurally 
similar heterocycles possessing different arrangements of heteroatoms has been extensively 
exploited in the design of new therapeutic agents. This strategy, applied to the purine scaffold, has 
led to the development of several blockbuster drugs and current therapeutic standards such as 
sildenafil and vardenafil for the treatment of erectile dysfunction,2 allopurinol recommended as the 
first choice for the chronic gout therapy,3 ibrutinib for the leukaemia therapy,4 and temozolomide 
for the treatment of brain cancers; see Figure 1 for chemical diagrams.5 In the area of purine 
isosteres, we have a sustained interest towards 1,3,5-triazine-based purine-like scaffolds.6 Among 
them, 5-azapurine (1,2,4-triazolo[1,5-a][1,3,5]triazine) and 5-aza-9-deazapurine (pyrazolo[1,5-
a][1,3,5]triazine) have been recognised as the most promising skeletons for the construction of new 
bioactive compounds.7-9 Recently, pyrazolo[1,5-a][1,3,5]triazine derivatives were reported to be 
useful as cyclin-dependent kinase inhibitors10, tyrosine threonine kinase inhibitors11, 
phosphodiesterase (PDE10 and PDE4) inhibitors12, cannabinoid (CB1) receptor antagonists13, and corticotrophin-releasing factor (CRF1) receptor antagonists14. Their anti-proliferative15 and antiviral16 properties have also been well documented. 
 
 
Figure 1. Therapeutically renowned purine isosteres. 
 
Herein, we report results of our experiments on the synthesis pyrazolo[1,5-a][1,3,5]triazines using a 
multicomponent reaction of 5-aminopyrazole-4-carboxylates (1) with trimethyl orthoformate and 
cyanamide. Possessing several reactive centres in their structure, 5-aminopyrazole-4-carboxylates 
(1) have found many successful applications as building blocks for the construction of fused 
heterocyclic systems.17-19 However, no reports on multicomponent reactions of these compounds 
are available. A combination of multiple reactive centres in 5-aminopyrazole-4-carboxylates (1) 
increases the complexity of potential multicomponent processes making it difficult to predict their 
outcome and achieve selectivity of the reactions.  
2. Results and Discussion  
2.1 Stepwise synthesis of 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates (4) 
In stepwise approaches, 5-aminopyrazole-4-carboxylates (1) were reported to react with triethyl 
orthoformate or its synthetic equivalents (for example, DMF-DMA) followed by the reaction of the 
intermediates 2 with N-nucleophiles to afford pyrazolo[3,4-d]pyrimidin-4-ones (3) (Scheme 1).18,19 
 
 
Scheme 1.  
 
Designing our multicomponent reaction, we decided to explore initially a stepwise synthesis of the 
targeted 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates (4). It was reported recently that 
aminoazoles could be converted to the corresponding N,N-dimethylformamidines, which upon 
subsequent treatment with cyanamide in the presence of sodium methoxide produced azolo-fused 
amino-1,3,5-triazines. 1,20 Initially, we applied similar conditions to our model substrate 1a preparing 
amidine 2a, which successfully reacted with cyanamide to afford the desirable product 4a in 35% 
overall yield (Scheme 2). Both steps were also performed at higher temperature using microwave 
irradiation. Amidine 2a was successfully prepared via the condensation of ethyl 5-amino-3-
(phenylamino)pyrazole-4-carboxylate (1a) with DMF-DMA under microwave irradiation. To our 
satisfaction, the subsequent microwave-assisted reaction of amidine 2a and cyanamide in ethanol 
lead to the formation of 4a even in the absence of base. Interestingly, in our attempt to use 
methanol as a solvent for the reaction of amidine 2a and cyanamide, a mixture of two different 
products was isolated: desired compound 4a and methyl 4-amino-7-(phenylamino)pyrazolo[1,5-
a][1,3,5]triazine-8-carboxylate (4b) (Scheme 3). It appeared that under the reaction conditions, a 
partial transesterification with the solvent took place replacing the ethyl ester group to the methyl 
one. 
It should be noted that when we performed a one-pot, three-component synthesis of another 
formamidine (2b) from 1a, triethyl orthoformate, and morpholine under microwave irradiation in 
methanol, no transesterification products were isolated at this step (Scheme 2). The microwave-
assisted reaction of 2b with cyanamide in ethanol led to the formation of 4a. However, the same 
reaction in methanol afforded a mixture of 4a and its methyl ester analogue 4b (Scheme 3).  
We proposed that the ester group reactivity increased after the triazine ring annulations and the 
transesterification took place in the presence of the base (dimethylamine or morpholine), which was 
released during the reaction. This assumption was further confirmed by the experiment when a 
similar reaction of 2a was performed in methanol using a stronger base (sodium methoxide) 
(Scheme 3). The methyl ester 4b was isolated from the reaction without even traces of 4a. 
Moreover, under these conditions, the transesterification occurred even before the trazine ring 
closure as indicated by the isolation of a side-product viz. methyl 5-amino-3-(phenylamino)pyrazole-
4-carboxylate (1b) together with 4b.  
 
 
Scheme 2.  
 
Scheme 3.  
 
2.2 One-pot, three-component synthesis of 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates (4) 
Following the successful 1,3,5-triazine ring annulation onto 5-aminopyrazole-4-carboxylates using 
step-wise approaches, we decided to conduct a one-pot, three-component reaction of 5-
aminopyrazole-4-carboxylates (1a) with DMF-DMA and cyanamide under microwave irradiation 
(Scheme 4). To our satisfaction, we found that this reaction in methanol proceeded selectively to 
form ethyl 4-amino-7-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4a) albeit in low 
isolated yield (<5%). No traces of pyrazolo[3,4-d]pyrimidines or methyl ester analogue (4b) were 
detected. The analysis of the crude reaction mixture identified that most of 1a remained unreacted. 
The absence of 4b as a side product in the reaction mixture could be explained by the limited 
conversion of 1a to 4a, which is probably required for the successful transesterification under these 
conditions.  
 
Scheme 4. One-pot, multicomponent reactions of ethyl 5-amino3-phenylaminopyrazole-4-
carboxylate (1a).  
 
In attempts to improve yields and avoid potential base-catalysed transesterification, we performed a 
similar multicomponent reaction using trimethyl orthoformate instead of DMF-DMA. Under identical 
conditions, the one-pot, three-component, microwave-assisted reaction of 5-amino-3-
phenylaminopyrazole-4-carboxylate (1a), trimethyl orthoformate and cyanamide afforded the 
desired 4a in good yield (79%). The product 4a was isolated via simple filtration in high purity 
without traces of other side products.  
Exclusive formation of 4a confirmed the regio- and chemoselectivity of the multicomponent reaction 
under these conditions. Variations in the ratio of reagents or changing the solvent did not lead to 
further improvements in the reaction outcome (Table 1). Notably, the yield of 4a in the reaction 
performed using the one-pot, multicomponent format was higher compared to the overall yield in 
the stepwise approach.  
 
Table 1. Optimization of conditions for the model multicomponent reaction of 1a. 
 
Entry Solvent Ratio of 1a: HC(OMe)3 : NCNH2 Yield (%) 
1 MeOH 1 : 1.8 : 1.2 38 
2 MeCN 1 : 1.8 : 1.2 25 
3 THF 1 : 1.8 : 1.2 35 
4 MeOH 1 : 2 : 2 61 
5 MeOH 1 : 2.5 : 2.5 71 
6 MeOH 1 : 3 : 3 79 
7 MeOH 1 : 3.5 : 3.5  71 
*The reaction was performed using a Discover SP CEM microwave synthesizer using 1 mmol of 1a in 
2 mL of the specified solvent. 
 
The three-component reaction of ethyl 5-amino-3-(phenylamino)pyrazole-4-carboxylate (1a), 
trimethyl orthoformate and cyanamide under microwave irradiation was also performed using 
identical conditions in three different models of microwave synthesizers: Discover SP (CEM), 
Monowave 450 (Anton Paar), and Initiator+ (Biotage). The reactions were conducted in triplicates in 
each reactor demonstrating good reproducibility of the developed method (Figure 2). 
 
 
* The reaction was performed using 1 mmol of 1a, 3 mmol of HC(OMe)3 and 3 mmol of H2NCN in 2 
mL of MeOH under microwave irradiaton at 150 °C for 25 min 
Figure 2. One-pot, multicomponent reaction of 1a, trimethyl orthoformate and cyanamide using 
three different models of microwave synthesizers.  
 
Scaling up the model multicomponent reaction from 1 mmol to 10 mmol of 1a under identical 
microwave conditions afforded the same product 4a in high purity and similar yield (76%). 
Next, the scope of our one-pot, multicomponent reaction was explored using as substrates various 
substituted methyl and ethyl esters of 5-aminopyrazole-4-carboxylates (1a-x), which were prepared 
according to the method we developed recently.21 The one-pot reaction of 5-aminopyrazole-4-
carboxylates (1a-x) with trimethyl orthoformate and cyanamide under the microwave irradiation 
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was found to proceed efficiently with the formation of desirable products 4a-x in yields up to 95% 
(Table 2). A variety of arylamino, alkylamino, and arylalkylamino substituents on the pyrazole ring 
were well tolerated. The reaction was selective and secondary amino groups of 4a-x remained 
intact. No transesterification products were detected when the multicomponent reactions of ethyl 
5-aminopyrazole-4-carboxylates were carried out in methanol under these conditions. Overall, the 
reaction was chemo- and regioselective and afforded interesting purine analogues in a single, 
relatively short and operationally simple step.  
 
Table 2.  
One-pot, three-component synthesis of 7-amino-substituted 4-aminopyrazolo[1,5-a][1,3,5]triazine-
8-carboxylates (4). 
 
Produc
t 
Structure Yield 
(%) 
Mp (°C) Produc
t 
Structure Yield 
(%) 
Mp (°C) 
4a 
 
79 235-237a 4m 
 
89 198-200d 
4b 
 
91 233-235b 4n 
 
80 264-266e 
4c 
 
79 250-252a 4o 
 
87 307-308d 
4d 
 
82 233-235a 4p 
 
65 233-235a 
4e 
 
74 250-252c 4q 
 
95 235-237a 
4f 
 
86 269-271a 4r 
 
79 238-240a 
4g 
 
83 260-262b 4s 
 
74 280-282b 
4h 
 
76 298-299d 4t 
 
86 298-300b 
4i 
 
82 233-235b 4u 
 
69 147-149a 
4j 
 
70 242-244a 4v 
 
92 106-108a 
4k 
 
72 246-248a 4w 
 
73 131-133a 
4l 
 
91 196-198a 4x 
 
92 200-202a 
Recrystallization solvents: a MeOH, b MeCN, c DMF & MeOH, e DMF & H2O, d DMF  
The structure assignments for the prepared 5-aza-9-deaza-adenines 4 were made on the basis of 
spectral data. The ester group remained intact in the reaction giving characteristic signals for 
ethoxycarbonyl and methoxycarbonyl groups in NMR spectra, particularly a triplet at 1.33 - 1.34 ppm 
and a quartet at 4.34 - 4.35 ppm or a singlet at 3.75-3.85 ppm for the corresponding alkyl fragment 
in 1H NMR spectra and a signal of the ester carbonyl carbon at 163.8-164.9 ppm in 13C NMR spectra 
of compounds 4. The band at 1630-1692 cm-1 in the IR spectra also indicated the ester group 
presence. The methine proton of the newly formed triazine ring appeared as a singlet at 8.10-8.25 
ppm in 1H NMR spectra. The primary amino group on the electron-deficient triazine ring of the 
prepared 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 4 was found to display a hindered 
rotation of the C-N bond. This restricted rotation made the amino group hydrogens magnetically 
non-equivalent resulting in appearance of the two broad signals at 7.83-8.50 ppm and 8.10-8.90 
ppm in the 1H NMR spectra. Considering polar properties of the solvent (DMSO-d6), this phenomenon is more likely to be attributed to the high level of delocalization of the electron pair on 
the amino group nitrogen atom, rather than the intramolecular hydrogen bonding observed in the 
solid state for one of the amino group hydrogens with the pyrazole ring nitrogen atom.  
 
2.3 Dynamic NMR spectroscopy experiments  
Recently, Hage et al.10b demonstrated an importance of the restricted rotation around the C-N bond 
for amino groups attached to purine-like scaffolds in the design of CDK5 inhibitors. Particularly, the 
rotational barrier was estimated for one molecule with the purine scaffold and another one being its 
5-aza-9-deaza-isostere (pyrazolo[1,5-a][1,3,5]triazine). A nearly ten-fold higher binding affinity of the 
5-aza-9-deazapurine towards CDK5 compared to the parent purine molecule was explained on the 
basis of some stiffening of the rotational barrier around the exocyclic C-N bond for the pyrazolo[1,5-
a][1,3,5]triazine derivative. Therefore, we performed the variable temperature (dynamic) NMR 
spectroscopy experiment,22 enabling the estimation of the free energy barrier for the rotation 
around the C-N bond of the amino group on the triazine ring, for three representative compounds 
from the library we prepared.  
The data were collected for compounds 4a, 4b and 4x at the temperature range 30-60 °C. On 
heating, the two signals of the amino group in 1H NMR spectra changed their shape and coalesced 
(Figure 3). The rate constant (k) values for the amino group rotation were estimated using the line-
shape analysis of the 1H NMR spectra obtained. Applying the Eyring equation23, corresponding 
activation enthalpy (∆H‡) and entropy (∆S‡) values were calculated (Table 3). These activation 
parameters were similar to those determined for 5-azapurine24 and 5-aza-9-deazapurine25 
derivatives bearing an adenine type of the amino group.  
 
Table 3. Activation parameters for the rotation of the primary amino group of some 4-
aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 4.  
 
Compound R1 R2 ∆G‡300, kJ mol-1 ∆H‡, kJ mol-1 ∆S‡, J K-1 mol-1 4a Ph Et -47.7 3.42 170.4 4b Ph Me -50.18 2.11 174.3 4x cyclo-Hex Et -49.23 3.69 176.4  
 
 
Figure 3. Temperature-dependant shapes of the primary amino group signals in the 1H NMR spectra 
of compounds 4a (a), 4b (b) and 4x (c)  
 
2.4 X-Ray crystallographic study of 4a 
Crystals of a representative product, 4a, were obtained and investigated by X-ray crystallography. 
The molecular structure is shown in Figure 4(a) from which it can be seen that the structure is as 
determined spectroscopically. The nine-atom fused ring system along with the appended amine 
group forms a planar residue [r.m.s. deviation of 0.0239 Å] and forms dihedral angles of 8.00(3) and 
8.75(8)° with the CO2 atoms of the ester and the pendent phenyl ring, respectively, indicating to a first approximation, the entire molecule is planar with the exception of the ethyl group which lies 
prime to the rest of the molecule [the C81–O82–C82–C83 torsion angle = -89.72(17)°]. An 
intramolecular amine-N7–H…O81(carbonyl) hydrogen bond that closes an S(6) loop is noted26. In the 
crystal, supramolecular layers parallel to [0 1 0] are formed, Figure 4(b), by amine-N41-
H…N(triazine), O81(carbonyl) hydrogen bonds26, indicating the carbonyl-O81 atom accepts two 
hydrogen bonds. 
 
Figure 4. (a) Molecular structure of 4a showing atom labelling and 70% probability displacement 
ellipsoids and (b) View of the supramolecular layer parallel to [0 1 0] in the crystal of 4a. The 
intramolecular amine-N7–H…O81(carbonyl), and intermolecular amine-N41-H…N(triazine) and 
amine-N41-H…O81(carbonyl) hydrogen bonds are shown as green, blue and orange dashed lines, 
respectively. 
 
3. Conclusion 
We have successfully developed a catalyst-free, highly selective, microwave-assisted method for the 
multicomponent synthesis of 7-amino substituted 4-aminopyrazolo[1,5-a][1,3,5]triazine-8-
carboxylates (4) employing easily accessible reagents. The method was proven to be practical due to 
operational economy and simplicity, short reaction time, good yields and high purity of adenine-like 
products. These features are attractive for organic and medicinal chemists aiming to the preparation 
of libraries of purine-related compounds for the drug discovery process. The structural features 
important for the drug design and development were also estimated for the prepared compounds.  
 
4. Experimental section 
4.1 General 
Melting points (uncorrected) were determined on a Stuart™ SMP40 automatic melting point 
apparatus. 1H and 13C NMR spectra were recorded on a Bruker Fourier spectrometer (300 MHz) 
using DMSO-d6 as a solvent and TMS as an internal reference. IR spectra were recorded using ATR sample base plate diamond Spectrum Two (PerkinElmer) FT-IR spectrometer and in KBr pellets using 
Varian 640-IR spectrophotometer. Microwave-assisted reactions were carried out in the closed 
vessel focused single mode using a Discover SP microwave synthesizer (CEM, USA) monitoring 
reaction temperature by equipped IR sensor. For the method validation, the model reaction was also 
carried out using Monowave 450 (Anton Paar, Austria) and Initiator+ (Biotage, Sweden) reactors. 
4.2 Dynamic NMR 
Dynamic NMR experiments and lineshape analysis for 4a, 4b and 4x were conducted on a Bruker 
Fourier spectrometer (300 MHz) using DMSO-d6 as a solvent and TMS as an internal reference at a temperature range of 27-60 °C. A temperature before coalescence point (27 °C) was chosen to fix 
parameters for the experiments (Fix Line Broadening parameter at 0.5 Hz). Reaction rate parameters 
of exchange process at 30-60 °C were obtained using the DNMR Lineshape Fitting module27 and 
plotting a graph of ln(k/T) vs 1/T. The activation parameters for the rotation around the C-NH2 bond were calculated using the Eyring equation. 
4.3 Synthesis of ethyl 3(5)-phenylamino-5(3)-[(dimethylmethylene)amino]-1H-pyrazole-4-carboxylate 
(2a) using conventional heating 
A mixture of ethyl 5-aminopyrazole-4-carboxylate 1a (246 mg, 1 mmol) and N,N-dimethylformamide 
dimethyl acetal (0.2 mL, 1.5 mmol) in toluene (5 mL) was heated under reflux for 1 h. After cooling, 
the precipitate was filtered and recrystallised from MeOH to give pure formamidine 2a. White solid, 
yield 61%, m.p. 150-152 °C (MeOH). 
1H NMR (300 MHz, DMSO-d6): δ 1.24 (3H, t, 3J = 7.1 Hz, CH3), 2.96 (3H, s, NMe), 3.05 (3H, s, NMe), 4.16 (2H, q, 3J = 7.1 Hz, CH2), 6.81 (2H, t, 3J = 7.3 Hz, H-4′), 7.23 (2H, t, 3J = 7.9 Hz, H-3′ and H-5′), 7.54 (2H, d, 3J = 7.7 Hz, H-2′ and H-6′), 7.95 (1H, s, CH), 8.40 (1H, s, NH), 11.75 (1H, s, NH). 13C NMR (75 
MHz, DMSO-d6): δ 13.9 (CH3), 33.5 (CH3), 39.6 (CH3), 58.8 (CH2), 85.9 (CH), 116.0 (C-2′ and C-6′), 119.2 (C-4′), 128.7 (C-3′ and C-5′), 141.6 (C-1′), 152.1 (C-3), 153.4 (C-5), 158.3 (C-4), 164.9 (C=O). 
Anal. Calcd.  
4.4 Synthesis of ethyl 3(5)-phenylamino-5(3)-[(dimethylmethylene)amino]-1H-pyrazole-4-carboxylate 
(2a) under microwave irradiation 
A mixture of ethyl 5-aminopyrazole-4-carboxylate 1a (246 mg, 1 mmol) with N,N-
dimethylformamide dimethyl acetal (0.2 mL, 1.5 mmol) in toluene (2 mL) were irradiated in a 10 mL 
seamless pressure vial using microwave system operating at maximal microwave power up to 150 W 
at 150 °C for 10 min. After cooling, the precipitate was filtered and recrystallised from MeOH to give 
compound identical to formamidine 2a obtained using conventional heating. Yield 55%. 
4.5 Synthesis of ethyl 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4a) from 
2a under conventional heating 
To the sodium ethoxide solution prepared by dissolving sodium (60 mg, 2.5 mmol) in abs. EtOH (5 
mL), formamidine 2a (301 mg, 1 mmol) and cyanamide (105 mg, 2.5 mmol) were added. The 
reaction mixture was heated under reflux for 24 h, cooled and the precipitate was filtered to obtain 
a compound, which was identical to 4a prepared using the multicomponent reaction. Yield 57%. 
4.6 Synthesis of ethyl 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4a) from 
2a under microwave irradiation 
A mixture of 2a (301 mg, 1 mmol) with cyanamide (126 mg, 3 mmol) in abs. ethanol (2 mL) were 
irradiated in a 10 mL seamless pressure vial using microwave system operating at maximal 
microwave power up to 150 W at 150 °C for 25 min. After cooling, the precipitate was filtered to 
obtain a compound, which was identical to 4a prepared using the multicomponent reaction. Yield 
35%. 
4.7 Synthesis of ethyl 3(5)-phenylamino-5(3)-[(morpholinomethylene)amino]-1H-pyrazole-4-
carboxylate (2b) under microwave irradiation 
A mixture of ethyl 5-aminopyrazole-4-carboxylate 1a (246 mg, 1 mmol) with triethylorthoformate 
(0.42 mL, 2.5 mmol) and morpholine (0.22 mL, 2.5 mmol) in methanol (2 mL) were irradiated in a 10 
mL seamless pressure vial using microwave system operating at maximal microwave power up to 
150 W at 150 °C for 20 min. After cooling, the precipitate was filtered and recrystallised from 
ethanol to give pure formamidine 2b. Light yellow solid, yield 51%, m.p. 191-192 °C (EtOH).  
1H NMR (300 MHz, DMSO-d6): δ 1.26 (3H, t, 3J = 7.1 Hz, CH3), 3.45-3.47 (2H, m, CH2), 3.63-3.66 (4H, m, (CH2)2), 4.18 (2H, q, 3J = 7.1 Hz, CH2), 6.81 (2H, t, 3J = 7.3 Hz, H-4′), 7.23 (2H, t, 3J = 7.9 Hz, H-3′ and H-5′), 7.55 (2H, d, 3J = 7.7 Hz, H-2′ and H-6′), 8.00 (1H, s, CH), 8.41 (1H, s, NH), 11.83 (1H, s, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 14.1 (CH3), 42.1 (CH2), 48.4 (CH2), 58.9 (CH2), 65.4 (CH2), 66.5 (CH2), 86.0 (CH), 116.1 (C-2′ and C-6′), 119.2 (C-4′), 128.7 (C-3′ and C-5′), 141.5 (C-1′), 152.2 (C-3), 153.0 (C-5), 
157.1 (C-4), 164.9 (C=O). Anal. Calcd.  
4.8 Synthesis of ethyl 4-amino-7-phenylaminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4a) from 
2b under microwave irradiation 
A mixture of 2b (343 mg, 1 mmol) with cyanamide (126 mg, 3 mmol) in abs. ethanol (2 mL) were 
irradiated in a 10 mL seamless pressure vial using microwave system operating at maximal 
microwave power up to 150 W at 150 °C for 25 min. After cooling, the precipitate was filtered to 
obtain a compound, which was identical to 4a prepared using the multicomponent reaction. Yield 
57%. 
4.9 General method for the microwave-assisted synthesis of 7-amino substituted 4-
aminopyrazolo[1,5-a][1,3,5]triazine-8-carboxylates 4 
A mixture of 5-aminopyrazole-8-carboxylate 1 (1 mmol), cyanamide (126 mg, 3 mmol) and 
trimethylorthoformate (0.35 mL, 3 mmol) in MeOH (2 mL) were irradiated in a 10 mL seamless 
pressure vial using microwave system operating at maximal microwave power up to 150 W at 150 °C 
for 25 min. After cooling, the precipitated product 4 was filtered and washed with cold MeOH and 
recrystallised from a suitable solvent. 
4.9.1 Ethyl 4-amino-7-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4a) 
White solid, yield 79%; mp 235-237 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 6.99 (1H, t, 3J = 7.3 Hz, H-4′), 7.33 (2H, t, 3J = 7.9 Hz, H-3′ and H-5′), 7.85 (2H, d, 3J = 7.7 Hz, H-2′ and H-6′), 8.22 (1H, s, H-2), 8.35 (1H, br s, NH), 8.84 (1H, br s, NH), 
9.00 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 59.7 (CH2) 86.3 (C-8), 117.6 (C-2′ and C-6′), 121.1 (C-4′), 128.9 (C-3′ and C-5′), 140.0 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.5 (C-7), 157.1 (C-2), 
164.4 (C=O). IR (ATR): ν 3608 (N-H), 3304 (N-H), 3063 (C-H), 1668 (C=O), 1557, 1511, 1463, 1367, 
1259, 1144 cm-1. Anal. Calcd. 
4.9.2 Methyl 4-amino-7-(phenylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4b) 
White solid, yield 91%; mp 233-235 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 3.85 (3H, s, CH3), 6.99 (1H, t, 3J = 7.4 Hz, H-4′), 7.34 (2H, t, 3J = 8.0 Hz, H-3′ and H-5′), 7.86 (2H, d, 3J = 7.7 Hz, H-2′ and 
H-6′), 8.21 (1H, s, H-2), 8.36 (1H, br s, NH), 8.86 (1H, br s, NH), 8.97 (1H, s, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 51.0 (CH3), 86.2 (C-8), 117.7 (C-2′ and C-6′), 121.2 (C-4′), 128.9 (C-3′ and C-5′), 139.8 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.5 (C-7), 157.1 (C-2), 164.8 (C=O). IR (KBr): ν 3605 (N-H), 3453 (N-H), 
3048 (C-H), 1674 (C=O), 1593, 1560, 1447, 1360, 1255, 1145 cm-1. Anal. Calcd. 
4.9.3 Ethyl 4-amino-7-[(2-fluorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4c) 
White solid, yield 79%; mp 250-252 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.34 (3H, t, 3J = 7.1 Hz, CH3), 4.35 (2H, q, 3J = 7.1 Hz, CH2),  6.96-7.04 (1H, m, H-4′), 7.21 (1H, t, 3J = 7.7 Hz, H-5′), 7.30 (1H, ddd, 4J = 1.3 Hz, 3 J = 8.1 Hz, 3JHF = 12.0 Hz, H-3′), 8.24 (1H, s, H-2), 8.47 (1H, br s, NH), 8.79 (1H, ddd, 
4J = 1.4 Hz, 3J = 8.8 Hz, 4JHF = 8.5 Hz, H-6′), 8.90 (1H, br s, NH), 9.30 (1H, d, 3JHF = 3.6 Hz, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.3 (CH3), 59.8 (CH2) 86.6 (C-8), 114.3 (d, 2JCF = 18.5 Hz, C-3′), 119.3 (d, 4JCF = 0.9 Hz, C-5′), 121.3 (d, 3JCF = 7.4 Hz, C-4′), 124.9 (d, 3JCF = 3.2 Hz, C-6′), 128.1 (d, 2JCF = 10.2 Hz, C-1′), 148.9 (C-8a), 150.0 (C-4), 151.0 (d, 1JCF = 240.7 Hz, C-2′), 155.1 (C-7), 157.3 (C-2), 164.5 (C=O). IR (ATR): ν 3355 (N-H), 3102 (N-H), 3075 (C-H), 1647 (C=O), 1599, 1551, 1451, 1361, 1259, 1150 cm-1. 
Anal. Calcd. 
4.9.4 Ethyl 4-amino-7-[(4-fluorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4d) 
Yellow solid, yield 82%; mp 233-235 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 7.12 (2H, dd, 3J = 8.9 Hz, 3JHF = 8.9 Hz, H-3′ and H-5′), 7.91 (2H, dd, 4JHF = 4.8 Hz, 3J = 9.2 Hz, H-2′ and H-6′), 8.22 (1H, s, H-2), 8.36 (1H, br s, NH), 8.84 (1H, br s, NH), 8.98 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 59.6 (CH2) 86.2 (C-8), 115.2 (d, 2JCF = 22.0 Hz, C-3′ and C-5′), 119.3 (d, 3JCF = 7.5 Hz, C-2′ and C-6′), 136.3 (d, 4JCF = 1.5 Hz, C-1′), 149.0 (C-8a), 149.9 (C-4), 155.5 (C-7), 156.9 (d, 1JCF = 239.1 Hz, C-4′), 157.2 (C-2), 164.3 (C=O). IR (ATR): ν 3459 (N-H), 3327 (N-H), 3043 (C-H), 1658 (C=O), 1563, 1504, 1451, 1364, 1252, 1143 cm-1. Anal. Calcd. 
4.9.5 Ethyl 4-amino-7-[(2-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4e) 
Light yellow solid, yield 74%; mp 250-252 °C (DMF & MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.34 (3H, t, 3J = 7.1 Hz, CH3), 4.36 (2H, q, 3J = 7.1 Hz, CH2), 7.02 (1H, ddd, 4J = 1.2 Hz, 3J = 7.7 Hz, 3J = 7.7 Hz, H-4′), 7.36 (1H, ddd, 4J = 1.1 Hz, 3J = 7.4 Hz, 3J = 8.3 Hz, H-5′), 7.52 (1H, dd, 4J = 1.4 Hz, 3J = 8.0 Hz, H-
3′), 8.25 (1H, s, H-2), 8.50 (1H, br s, NH), 8.91 (1H, dd, 4J = 1.3 Hz, 3J = 8.3 Hz, H-6′), 8.92 (1H, br s, 
NH), 9.67 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 59.8 (CH2) 86.6 (C-8), 119.0 (C-6′), 119.8 (C-4′), 121.8 (C-2′), 128.2 (C-5′), 128.8 (C-3′), 136.2 (C-1′), 148.9 (C-8a), 150.0 (C-4), 154.9 (C-7), 
157.4 (C-2), 164.5 (C=O). IR (ATR): ν 3473 (N-H), 3370 (N-H), 2919 (C-H), 1659 (C=O), 1587, 1551, 
1445, 1313, 1259, 1141 cm-1. Anal. Calcd. 
4.9.6 Ethyl 4-amino-7-[(3-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4f) 
White solid, yield 86%; mp 269-271 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.35 (2H, q, 3J = 7.1 Hz, CH2), 7.01 (1H, ddd, 4J = 0.8 Hz, 4J = 2.0 Hz, 3J = 7.9 Hz, H-4′), 7.33 (1H, t, 3J = 8.1 Hz, H-5′), 7.86 (1H, t, 4J = 2.0 Hz, H-2′), 7.92 (1H, ddd, 4J = 0.8 Hz, 4J = 2.2 Hz, 3J = 8.3 Hz, 
H-6′), 8.23 (1H, s, H-2), 8.47 (1H, br s, NH), 8.86 (1H, br s, NH), 9.10 (1H, s, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 14.4 (CH3), 59.8 (CH2) 86.7 (C-8), 116.4 (C-6′), 117.0 (C-2′), 121.0 (C-4′), 130.5 (C-5′), 133.4 (C-3′), 141.3 (C-1′), 149.1 (C-8a), 150.0 (C-4), 155.2 (C-7), 157.3 (C-2), 164.3 (C=O). IR (ATR): ν 
3470 (N-H), 3314 (N-H), 3024 (C-H), 1674 (C=O), 1589, 1549, 1457, 1321, 1244, 1143 cm-1. Anal. 
Calcd. 
4.9.7 Ethyl 4-amino-7-[(4-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4g) 
White solid, yield 83%; mp 260-262 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 7.32 (2H, d, 3J = 8.9 Hz, H-3′ and H-5′), 7.93 (2H, d, 3J = 9.0 Hz, H-2′ and H-6′), 8.22 (1H, s, H-2), 8.39 (1H, br s, NH), 8.86 (1H, br s, NH), 9.05 (1H, s, NH); 13C NMR (75 
MHz, DMSO-d6): δ 14.3 (CH3), 59.7 (CH2) 86.4 (C-8), 119.4 (C-2′ and C-6′), 124.6 (C-4′), 128.5 (C-3′ and C-5′), 138.8 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.3 (C-7), 157.2 (C-2), 164.3 (C=O). IR (ATR): ν 3453 (N-
H), 3316 (N-H), 3056 (C-H), 1648 (C=O), 1585, 1550, 1492, 1360, 1253, 1146 cm-1. Anal. Calcd. 
4.9.8 Methyl 4-amino-7-[(4-chlorophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4h) 
Light yellow solid, yield 76%; mp 298-299 °C (DMF & H2O); 1H NMR (300 MHz, DMSO-d6): δ 3.85 (3H, s, CH3), 7.32 (2H, d, 3J = 8.9 Hz, H-3′ and H-5′), 7.93 (2H, d, 3J = 9.0 Hz, H-2′ and H-6′), 8.21 (1H, s, H-2), 8.40 (1H, br s, NH), 8.88 (1H, br s, NH), 9.01 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 51.0 (CH3), 86.3 (C-8), 119.5 (C-2′ and C-6′), 124.7 (C-4′), 128.5 (C-3′ and C-5′), 138.8 (C-1′), 149.0 (C-8a), 149.9 
(C-4), 155.2 (C-7), 157.2 (C-2), 164.6 (C=O). IR (KBr): ν 3468 (N-H), 3427 (N-H), 3057 (C-H), 1685 
(C=O), 1657, 1587, 1457, 1359, 1257, 1145 cm-1. Anal. Calcd. 
4.9.9 Ethyl 4-amino-7-[(3-iodophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4i) 
Light yellow solid, yield 82%; mp 233-235 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 7.11 (1H, t, 3J = 8.0 Hz, H-5′), 7.33 (1H, ddd, 4J = 0.9 Hz, 4J = 1.5 Hz, 3J = 7.8 Hz, H-4′), 7.91 (1H, dd, 4J = 1.9 Hz, 4J = 1.9 Hz, H-2′), 8.19 (1H, ddd, 4J = 0.8 Hz, 4J = 2.2 
Hz, 3J = 8.3 Hz, H-6′), 8.23 (1H, s, H-2), 8.39 (1H, br s, NH), 8.85 (1H, br s, NH), 9.01 (1H, s, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 59.7 (CH2) 86.6 (C-8), 94.6 (C-3′), 117.1 (C-6′), 125.5 (C-2′), 129.9 (C-4′), 130.9 (C-5′), 141.2 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.1 (C-7), 157.2 (C-2), 164.2 (C=O). 
IR (KBr): ν 3570 (N-H), 3314 (N-H), 3056 (C-H), 1670 (C=O), 1581, 1556, 1455, 1334, 1257, 1144 cm-1. 
Anal. Calcd. 
4.9.10 Ethyl 4-amino-7-[(3-methylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4j) 
White solid, yield 70%; mp 242-244 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 2.35 (3H, s, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 6.80 (1H, d, 3J = 7.4 Hz, H-4′), 7.21 (1H, t, 3J = 7.8 Hz, H-5′), 7.53 (1H, s, H-2′), 7.71 (1H, dd, 4J = 2.0 Hz, 3J = 8.0 Hz, H-6′), 8.21 (1H, s, H-2), 8.33 (1H, 
br s, NH), 8.84 (1H, br s, NH), 8.97 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 21.0 (CH3), 59.7 (CH2) 86.3 (C-8), 114.8 (C-6′), 117.9 (C-2′), 122.0 (C-4′), 128.8 (C-5′), 138.3 (C-3′), 139.7 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.6 (C-7), 157.1 (C-2), 164.5 (C=O). IR (ATR): ν 3467 (N-H), 3331 (N-H), 
3036 (C-H), 1674 (C=O), 1578, 1550, 1451, 1319, 1262, 1138 cm-1. Anal. Calcd. 
4.9.11 Methyl 4-amino-7-[(3-methylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4k) 
White solid, yield 72%; mp 246-248 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 2.35 (3H, s, CH3), 3.85 (3H, s, CH3), 6.80 (1H, dd, 4J = 0.9 Hz, 3J = 7.5 Hz, H-4′), 7.21 (1H, t, 3J = 7.8 Hz, H-5′), 7.53 (1H, s, H-2′), 7.72 (1H, dd, 4J = 2.0 Hz, 3 J = 8.1 Hz, H-6′), 8.21 (1H, s, H-2), 8.34 (1H, br s, NH), 8.86 (1H, br s, 
NH), 8.93 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 21.0 (CH3), 51.0 (CH3), 86.1 (C-8), 114.8 (C-6′), 118.0 (C-2′), 122.0 (C-4′), 128.8 (C-5′), 138.3 (C-3′), 139.7 (C-1′), 149.1 (C-8a), 149.9 (C-4), 155.5 (C-7), 
157.1 (C-2), 164.9 (C=O). IR (KBr): ν 3461 (N-H), 3324 (N-H), 3012 (C-H), 1688 (C=O), 1598, 1568, 
1456, 1320, 1263, 1144 cm-1. Anal. Calcd. 
4.9.12 Ethyl 4-amino-7-[(4-methylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4l) 
White solid, yield 91%; mp 196-198 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 2.28 (3H, s, CH3), 4.33 (2H, q, 3J = 7.1 Hz, CH2), 7.13 (2H, d, 3J = 8.3 Hz, H-3′ and H-5′), 7.73 
(2H, d, 3J = 8.5 Hz, H-2′ and H-6′), 8.20 (1H, s, H-2), 8.31 (1H, br s, NH), 8.81 (1H, br s, NH), 8.91 (1H, s, 
NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 20.4 (CH3), 59.7 (CH2) 86.2 (C-8), 117.7 (C-2′ and C-6′), 129.4 (C-3′ and C-5′), 130.0 (C-4′), 137.4 (C-1′), 149.1 (C-8a), 149.9 (C-4), 155.7 (C-7), 157.2 (C-2), 
164.5 (C=O). IR (ATR): ν 3428 (N-H), 3343 (N-H), 3060 (C-H), 1668 (C=O), 1590, 1554, 1448, 1319, 
1259, 1144 cm-1. Anal. Calcd. 
4.9.13 Ethyl 4-amino-7-[(4-isopropylphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4m) 
White solid, yield 89%; mp 198-200 °C (DMF & H2O); 1H NMR (300 MHz, DMSO-d6): δ 1.21 (6H, d, 3J = 6.9 Hz, (CH3)2), 1.33 (3H, t, 3J = 7.1 Hz, CH3), 2.87 (1H, m, 3J = 6.9 Hz, CH) 4.34 (2H, q, 3J = 7.1 Hz, CH2), 7.19 (2H, d, 3J = 8.5 Hz, H-3′ and H-5′), 7.75 (2H, d, 3J = 8.6 Hz, H-2′ and H-6′), 8.20 (1H, s, H-2), 8.28 
(1H, br s, NH), 8.81 (1H, br s, NH), 8.91 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 24.0 ((CH3)2), 32.6 (CH), 59.6 (CH2) 86.2 (C-8), 117.7 (C-2′ and C-6′), 126.6 (C-3′ and C-5′), 137.6 (C-1′), 141.1 (C-4′), 149.0 (C-8a), 149.8 (C-4), 155.6 (C-7), 157.1 (C-2), 164.5 (C=O). IR (KBr): ν 3346 (N-H), 
3144 (N-H), 2959 (C-H), 1680 (C=O), 1591, 1563, 1451, 1358, 1251, 1138 cm-1. Anal. Calcd. 
4.9.14 Ethyl 4-amino-7-[(2-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4n) 
Yellow solid, yield 80%; mp 264-266 °C (DMF); 1H NMR (300 MHz, DMSO-d6): δ 1.34 (3H, t, 3J = 7.1 Hz, CH3), 3.93 (3H, s, OCH3) 4.34 (2H, q, 3J = 7.1 Hz, CH2), 6.92-7.06 (3H, m, H-3′, H-4′ and H-5′), 8.22 (1H, s, H-2), 8.38 (1H, br s, NH), 8.67-8.70 (1H, m, H-6′), 8.83 (1H, br s, NH), 9.46 (1H, s, NH); 13C NMR 
(75 MHz, DMSO-d6): δ 14.4 (CH3), 55.8 (OCH3), 59.6 (CH2) 86.6 (C-8), 110.0 (C-3′), 117.4 (C-6′), 120.9 (C-4′ and C-5′), 129.2 (C-1′), 146.8 (C-2′), 149.1 (C-8a), 149.9 (C-4), 155.2 (C-7), 157.1 (C-2), 164.0 
(C=O). IR (ATR): ν 3396 (N-H), 3330 (N-H), 3127 (C-H), 1637 (C=O), 1594, 1552, 1448, 1355, 1250, 
1144 cm-1. Anal. Calcd. 
4.9.15 Methyl 4-amino-7-[(2-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4o) 
Light yellow solid, yield 87%; mp 307-308 °C (DMF & H2O); 1H NMR (300 MHz, DMSO-d6): δ 3.85 (3H, s, CH3), 3.93 (3H, s, OCH3), 6.92-7.07 (3H, m, H-3′, H-4′ and H-5′), 8.20 (1H, s, H-2), 8.41 (1H, br s, NH), 8.65-8.68 (1H, m, H-6′), 8.86 (1H, br s, NH), 9.50 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 51.1 (CH3), 55.9 (OCH3), 86.4 (C-8), 110.0 (C-3′), 117.4 (C-6′), 120.9 (C-4′ and C-5′), 129.1 (C-1′), 146.8 (C-2′), 149.0 (C-8a), 149.9 (C-4), 155.3 (C-7), 157.1 (C-2), 164.7 (C=O). IR (KBr): ν 3386 (N-H), 3329 (N-H), 
3067 (C-H), 1645 (C=O), 1600, 1560, 1457, 1359, 1258, 1150 cm-1. Anal. Calcd. 
4.9.16 Ethyl 4-amino-7-[(3-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4p) 
Yellow solid, yield 65%; mp 233-235 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 3.79 (3H, s, OCH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 6.57 (1H, ddd, 4J = 0.7 Hz, 4 J = 2.3 Hz, 3J = 8.2 Hz, H-4′), 7.20-7.26 (2H, m, H-2′ and H-5′), 7.57 (1H, ddd, 4J = 0.7 Hz, 4J = 2.1 Hz, 3J = 8.1 Hz, H-6′), 
8.21 (1H, s, H-2), 8.27 (1H, br s, NH), 8.82 (1H, br s, NH), 9.01 (1H, s, NH); 13C NMR (75 MHz, DMSO-
d6): δ 14.3 (CH3), 55.0 (OCH3), 59.7 (CH2) 86.4 (C-8), 103.2 (C-2′), 107.1 (C-4′), 110.3 (C-6′), 129.8 (C-5′), 140.9 (C-1′), 149.0 (C-8a), 149.9 (C-4), 155.5 (C-7), 157.1 (C-2), 159.8 (C-3′), 164.5 (C=O). IR (ATR): 
ν 3459 (N-H), 3340 (N-H), 2987 (C-H), 1676 (C=O), 1596, 1552, 1448, 1371, 1199, 1081 cm-1. Anal. 
Calcd. 
4.9.17 Ethyl 4-amino-7-[(4-methoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4q) 
Yellow solid, yield 95%; mp 235-237 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 3.75 (3H, s, OCH3), 4.33 (2H, q, 3J = 7.1 Hz, CH2), 6.89 (2H, d, 3J = 9.1 Hz, H-3′ and H-5′), 7.79 (2H, d, 3J = 9.1 Hz, H-2′ and H-6′), 8.20 (1H, s, H-2), 8.26 (1H, br s, NH), 8.80 (1H, br s, NH), 8.83 (1H, s, 
NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 55.1 (OCH3), 59.6 (CH2) 86.0 (C-8), 114.0 (C-3′ and C-
5′), 119.0 (C-2′ and C-6′), 133.3 (C-1′), 149.0 (C-8a), 149.8 (C-4), 153.8 (C-4′), 155.7 (C-7), 157.0 (C-2), 
164.4 (C=O). IR (ATR): ν 3391 (N-H), 3328 (N-H), 3172 (C-H), 1630 (C=O), 1591, 1560, 1453, 1363, 
1247, 1155 cm-1. Anal. Calcd. 
4.9.18 Ethyl 4-amino-7-[(4-trifluoromethoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-
carboxylate (4r) 
White solid, yield 79%; mp 235-237 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 4.34 (2H, q, 3J = 7.1 Hz, CH2), 7.27 (2H, d, 3J = 8.3 Hz, H-3′ and H-5′), 8.01 (2H, d, 3J = 9.1 Hz, H-2′ and H-6′), 8.23 (1H, s, H-2), 8.39 (1H, br s, NH), 8.87 (1H, br s, NH), 9.10 (1H, s, NH); 13C NMR (75 
MHz, DMSO-d6): δ 14.3 (CH3), 59.7 (CH2) 86.5 (C-8), 119.0 (C-2′ and C-6′), 120.2 (q, 1JCF = 255.1 Hz, CF3), 121.6 (C-3′ and C-5′), 139.1 (C-1′), 142.1 (q, 3JCF = 1.6 Hz, C-4′), 149.0 (C-8a), 149.9 (C-4), 155.3 (C-7), 157.2 (C-2), 164.3 (C=O). IR (ATR): ν 3461 (N-H), 3322 (N-H), 3045 (C-H), 1668 (C=O), 1596, 
1563, 1454, 1361, 1247, 1147 cm-1. Anal. Calcd. 
4.9.19 Methyl 4-amino-7-[(4-trifluoromethoxyphenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-
carboxylate (4s) 
Light yellow solid, yield 74%; mp 280-282 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 3.85 (3H, s, CH3), 7.27 (2H, d, 3J = 8.5 Hz, H-3′ and H-5′), 8.02 (2H, d, 3J = 9.1 Hz, H-2′ and H-6′), 8.22 (1H, s, H-2), 8.40 (1H, br s, NH), 8.89 (1H, br s, NH), 9.06 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 51.1 (CH3), 86.3 (C-8), 119.1 (C-2′ and C-6′), 120.2 (q, 1JCF = 254.8 Hz, CF3), 121.6 (C-3′ and C-5′), 139.1 (C-1′), 142.1 (q, 3JCF = 1.8 Hz, C-4′), 149.0 (C-8a), 149.9 (C-4), 155.2 (C-7), 157.2 (C-2), 164.6 (C=O). IR (KBr): ν 3463 (N-H), 3325 (N-H), 3078 (C-H), 1692 (C=O), 1600, 1575, 1459, 1359, 1256, 1145 cm-1. Anal. 
Calcd. 
4.9.20. Ethyl 4-amino-7-[(4-acetamidophenyl)amino]pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4t) 
Grey solid, yield 86%; mp 298-300 °C (MeCN); 1H NMR (300 MHz, DMSO-d6): δ 1.33 (3H, t, 3J = 7.1 Hz, CH3), 2.03 (3H, s, CH3), 4.33 (2H, q, 3J = 7.1 Hz, CH2), 7.56 (2H, d, 3J = 9.0 Hz, H-3′ and H-5′), 7.79 (2H, d, 3J = 9.0 Hz, H-2′ and H-6′), 8.21 (1H, s, H-2), 8.33 (1H, br s, NH), 8.82 (1H, br s, NH), 8.90 (1H, s, NH) 
9.82 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 23.8 (CH3), 59.6 (CH2) 86.1 (C-8), 117.8 (C-2′ and C-6′), 119.6 (C-3′ and C-5′), 133.2 (C-4′), 135.2 (C-1′), 149.0 (C-8a), 149.8 (C-4), 155.5 (C-7), 
157.1 (C-2), 164.4 (C=O), 167.7 (C=O). IR (KBr): ν 3607 (N-H), 3460 (N-H), 3296 (N-H), 3097 (C-H), 
1666 (C=O), 1572 (C=O), 1515, 1453, 1367, 1262, 1147 cm-1. Anal. Calcd. 
4.9.21 Ethyl 4-amino-7-(benzylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4u) 
White solid, yield 69%; mp 147-149 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.27 (3H, t, 3J = 7.1 Hz, CH3), 4.25 (2H, q, 3J = 7.1 Hz, CH2), 4.60 (2H, d, 3J = 6.3 Hz, CH2), 6.93 (1H, t, 3J = 6.3 Hz, NH), 7.24 (1H, t, 3J = 7.2 Hz, H-4′), 7.33 (2H, t, 3J = 7.3 Hz, H-3′ and H-5′), 7.43 (2H, d, 3J = 7.0 Hz, H-2′ and H-6′), 
7.85 (1H, br s, NH), 8.11 (1H, s, H-2), 8.61 (1H, br s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.5 (CH3), 45.2 (CH2), 59.2 (CH2) 85.7 (C-8), 126.8 (C-4′), 127.6 (C-2′ and C-6′), 128.3 (C-3′ and C-5′), 139.8 (C-1′), 149.6 (C-8a), 149.9 (C-4), 156.5 (C-7), 159.6 (C-2), 164.0 (C=O). IR (ATR): ν 3452 (N-H), 3389 (N-H), 
3030 (C-H), 1672 (C=O), 1591, 1562, 1497, 1361, 1252, 1140 cm-1. Anal. Calcd. 
4.9.22 Ethyl 4-amino-7-(phenethylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4v) 
Yellow solid, yield 92%; mp 106-108 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.25 (3H, t, 3J = 7.1 Hz, CH3), 2.95 (2H, t, 3J = 7.4 Hz, CH2), 3.61 (2H, q, 3J = 6.9 Hz, CH2), 4.23 (2H, q, 3J = 7.1 Hz, CH2), 6.48 (1H, t, 3J = 5.9 Hz, NH), 7.20-7.32 (5H, m, H-1′, H-2′, H-3′, H-4′, H-5′), 7.88 (1H, br s, NH), 8.11 (1H, s, 
H-2), 8.61 (1H, br s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 34.9 (CH2), 43.3 (CH2), 59.0 (CH2) 
85.6 (C-8), 126.0 (C-4′), 128.2 (C-2′ and C-6′), 128.7 (C-3′ and C-5′), 139.4 (C-1′), 149.5 (C-8a), 149.8 
(C-4), 156.4 (C-7), 159.4 (C-2), 163.8 (C=O). IR (ATR): ν 3437 (N-H), 3253 (N-H), 3060 (C-H), 1680 
(C=O), 1590, 1560, 1497, 1370, 1274, 1138 cm-1. Anal. Calcd. 
4.9.23 Methyl 4-amino-7-(phenylethylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4w) 
White solid, yield 73%; mp 131-133 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 2.95 (2H, t, 3J = 7.4 Hz, CH2), 3.61 (2H, q, 3J = 6.9 Hz, CH2), 3.75 (3H, s, CH3), 6.51 (1H, t, 3J = 5.9 Hz, NH), 7.20-7.32 (5H, m, H-1′, H-2′, H-3′, H-4′, H-5′), 7.90 (1H, br s, NH), 8.10 (1H, s, H-2), 8.64 (1H, br s, NH); 13C NMR (75 
MHz, DMSO-d6): δ 34.9 (CH2), 43.4 (CH2), 50.5 (CH3) 85.4 (C-8), 126.0 (C-4′), 128.2 (C-2′ and C-6′), 128.7 (C-3′ and C-5′), 139.4 (C-1′), 149.5 (C-8a), 149.9 (C-4), 156.3 (C-7), 159.4 (C-2), 164.2 (C=O). IR 
(KBr): ν 3465 (N-H), 3391 (N-H), 3024 (C-H), 1688 (C=O), 1657, 1598, 1498, 1361, 1265, 1143 cm-1. 
Anal. Calcd. 
4.9.24 Ethyl 4-amino-7-(cyclohexylamino)pyrazolo[1,5-a][1,3,5]triazine-8-carboxylate (4x) 
White solid, yield 92%; mp 200-202 °C (MeOH); 1H NMR (300 MHz, DMSO-d6): δ 1.28 (3H, t, 3J = 7.1 Hz, CH3), 1.28-1.71 (8H, m, ((CH2)4), 1.98-2.01 (2H, m, CH2), 3.69-3.78 (1H, m, CHNH), 4.25 (2H, q, 3J = 7.1 Hz, CH2), 6.31 (1H, t, 3J = 8.2 Hz, NH), 7.83 (1H, br s, NH), 8.10 (1H, s, H-2), 8.59 (1H, br s, NH); 13C NMR (75 MHz, DMSO-d6): δ 14.4 (CH3), 24.3 ((CH2)2), 25.2 (CH2), 32.4 ((CH2)2), 49.9 (CHNH), 59.1 (CH2) 85.4 (C-8), 149.5 (C-8a), 149.7 (C-4), 156.3 (C-7), 158.8 (C-2), 164.2 (C=O). IR (ATR): ν 3456 (N-H), 3380 (N-H), 3043 (C-H), 1660 (C=O), 1597, 1561, 1491, 1351, 1258, 1139 cm-1. Anal. Calcd. 
4.10 X-Ray crystallography of 4a  
Intensity data for 4a were measured at T = 100(2) K on a SuperNova Dual AtlasS2 diffractometer 
fitted with Cu K radiation so that max was 75.1°.  Data reduction, including absorption correction, was accomplished with CrysAlis Pro [28].  Of the 13386 measured reflections, 2772 were unique (Rint = 0.036) and of these, 2453 data satisfied the I  2(I) criterion.  The structure was solved by direct-
methods [29] and refined (anisotropic displacement parameters, C-bound H atoms in the riding 
model approximation, N-bound H atoms with N–H = 0.88-0.91±0.01 Å and a weighting scheme w = 
1/[2(Fo2) + 0.051P2 + 0.857P] where P = (Fo2 + 2Fc2)/3) on F2 [30].  Based on the refinement of 209 parameters, the final values of R and wR (all data) were 0.043 and 0.114, respectively.  The 
molecular structure diagram was generated with ORTEP for Windows [31] and the packing diagram 
with DIAMOND [32]. 
Crystal data for C14H14N6O2 (4a): M = 298.31, monoclinic, P21/n, a = 6.65750(10), b = 20.0193(4), c = 10.2489(2) Å,  = 92.161(2)˚, V = 1364.99(4) Å3, Z = 4, Dx = 1.452 g cm-3, F(000) = 624,  = 0.854 mm-1.  CCDC deposition number: 1817291. 
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